Please assess the completion status of the following clinical trial:

Trial Title: Improved Induction and Maintenance Immunosuppression in Kidney Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Primary renal transplant recipient for end-stage renal disease~Exclusion Criteria:~* Recipient age \< 18 years or \> 65 years~* Previous history of CMV disease~* Hepatitis B and C recipients~* Primary disease states that require steroids for immunosuppression~* Re-transplant with immunological cause of renal or pancreas loss~* Non heart beating donors~* Recipient of pediatric en bloc kidneys~* Recipient with a Panel Reactive Antibody (PRA) score \>75%~* Patients who have received 3 or more prior transplants, excluding pancreas~* Patients who are past recipients of other solid organ transplants~* Previous history of BK virus~* Previous treatment with Thymoglobulin~* Allergy to rabbits~* Simultaneous Kidney/Pancreas transplantation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Kidney transplant recipients given a single large dose of rabbit anti-thymocyte globulin (rATG) and maintained on tacrolimus and sirolimus for chronic immunosuppression.
- Group 2 (Type: EXPERIMENTAL): Kidney transplant recipients given 4 small doses of rabbit anti-thymocyte globulin (rATG) and maintained on tacrolimus and sirolimus for chronic immunosuppression.
- Group 3 (Type: EXPERIMENTAL): Kidney transplant recipients given a single large dose of rabbit anti-thymocyte globulin (rATG) and maintained on tacrolimus and sirolimus for chronic immunosuppression until tacrolimus is replaced with mycophenolate mofetil after about 6 months.
- Group 4 (Type: EXPERIMENTAL): Kidney transplant recipients given 4 small doses of rabbit anti-thymocyte globulin (rATG) and maintained on tacrolimus and sirolimus for chronic immunosuppression until tacrolimus is replaced with mycophenolate mofetil after about 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).